COR Quote, Financials, Valuation and Earnings

Cardinal Health has a net margin of 0.6% compared to Cencora's net margin of 0.72%. Cencora's return on equity of 155.22% beat Cardinal Health's return on equity of --.

Cencora has a consensus price target of $295.02, signalling upside risk potential of 3.62%. On the other hand Cardinal Health has an analysts' consensus of $143.07 which suggests that it could grow by 6.43%. Given that Cardinal Health has higher upside potential than Cencora, analysts believe Cardinal Health is more attractive than Cencora.

Cencora has a beta of 0.547, which suggesting that the stock is 45.294% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.803%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.75%. Cardinal Health offers a yield of 1.5% to investors and pays a quarterly dividend of $0.51 per share. Cencora pays 27.58% of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $81.5B, which are larger than Cardinal Health quarterly revenues of $55.3B. Cencora's net income of $488.6M is higher than Cardinal Health's net income of $400M. Notably, Cencora's price-to-earnings ratio is 40.50x while Cardinal Health's PE ratio is 25.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 0.15x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of 0.6% compared to Cencora's net margin of -72.93%. Cencora's return on equity of 155.22% beat Standard BioTools's return on equity of -36.54%.

Cencora has a consensus price target of $295.02, signalling upside risk potential of 3.62%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 91.53%. Given that Standard BioTools has higher upside potential than Cencora, analysts believe Standard BioTools is more attractive than Cencora.

Cencora has a beta of 0.547, which suggesting that the stock is 45.294% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.101%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.75%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $81.5B, which are larger than Standard BioTools quarterly revenues of $46.7M. Cencora's net income of $488.6M is higher than Standard BioTools's net income of -$34.1M. Notably, Cencora's price-to-earnings ratio is 40.50x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 2.51x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.6% compared to Cencora's net margin of 0.92%. Cencora's return on equity of 155.22% beat McKesson's return on equity of --.

Cencora has a consensus price target of $295.02, signalling upside risk potential of 3.62%. On the other hand McKesson has an analysts' consensus of $703.18 which suggests that it could grow by 1.58%. Given that Cencora has higher upside potential than McKesson, analysts believe Cencora is more attractive than McKesson.

Cencora has a beta of 0.547, which suggesting that the stock is 45.294% less volatile than S&P 500. In comparison McKesson has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.561%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.75%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Cencora pays 27.58% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $81.5B, which are smaller than McKesson quarterly revenues of $95.3B. Cencora's net income of $488.6M is lower than McKesson's net income of $879M. Notably, Cencora's price-to-earnings ratio is 40.50x while McKesson's PE ratio is 31.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0.6% compared to Cencora's net margin of --. Cencora's return on equity of 155.22% beat Pineapple's return on equity of --.

Cencora has a consensus price target of $295.02, signalling upside risk potential of 3.62%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora has higher upside potential than Pineapple, analysts believe Cencora is more attractive than Pineapple.

Cencora has a beta of 0.547, which suggesting that the stock is 45.294% less volatile than S&P 500. In comparison Pineapple has a beta of 32.190, suggesting its more volatile than the S&P 500 by 3119.041%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.75%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $81.5B, which are larger than Pineapple quarterly revenues of --. Cencora's net income of $488.6M is higher than Pineapple's net income of --. Notably, Cencora's price-to-earnings ratio is 40.50x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 32.44x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.